Although several favorable properties of SARS-CoV-2-specific T cells raised by COVID-19 vaccination in anti-TNF-treated IBD patients were identified, their independent impact on protection from disease is difficult to confidently ascertain. The gene discussed is TNF; the disease is inflammatory bowel disease.